Trials
May 13, 2025
Ka Yan, Nessa Ikani, Cleoputri Yusainy et al.
1 citation
Elevated levels of stress, anxiety, and depression persist among undergraduate students in Eastern countries, including Indonesia. Access to mental healthcare resources, however, remains difficult and costly for most young people. Furthermore, there is a strong tendency to avoid seeking professional help. The primary aim of this study is to investigate the effects of a brief 14-day online...
Journal of psychopharmacology (Oxford, England)
April 25, 2025
Jolien Ke Veraart, Sanne Y Smith-Apeldoorn, Annemarie van der Meij et al.
6 citations
Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting. Here we present results from a relatively large naturalistic study to evaluate the effectiveness, tolerability, and safety of oral esketamine in patients with TRD. One...
Psychiatry Research
March 1, 2025
Juliana Lima Constantino, Martijn Godschalk, Jens H van Dalfsen et al.
14 citations
Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression (TRD). Yet around 50% of the individuals with TRD do not respond to (es)ketamine. Elucidating predictors of response and remission could improve treatment outcomes at the individual level by defining subpopulations that are most likely to...
Molecular Psychiatry
September 1, 2024
Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis et al.
23 citations
About one-third of patients with depression do not achieve adequate response to current treatment options. Although intravenous and intranasal administrations of (es)ketamine have shown antidepressant properties, their accessibility and scalability are limited. We investigated the efficacy, safety, and tolerability of generic oral esketamine in patients with treatment-resistant depression (TRD)...
Mindfulness
July 1, 2024
Jelle Lubbers, Philip Spinhoven, Mira B. Cladder-Micus et al.
Abstract Objectives Mindfulness-Based Cognitive Therapy (MBCT) reduces recurrence and current depressive symptoms in patients with major depressive disorder (MDD). To understand how and for whom MBCT works, a person-centered approach focusing on mindfulness profiles can be useful. Four mindfulness profiles, each associated differently with mental health outcomes, have previously been...
Mindfulness
February 1, 2024
Jelle Lubbers, Philip Spinhoven, Mira B. Cladder-Micus et al.
Abstract Objectives Mindfulness is a multifaceted concept which might be best captured by person-centered profiles rather than by variable-centered assessment of its subcomponents. Patients with different mindfulness profiles may vary in mental health status and might experience differential clinical outcomes of Mindfulness-Based Cognitive Therapy (MBCT). We therefore aimed to assess the...
Depression and Anxiety
2024
Jelle Lubbers, Dirk E. M. Geurts, Philip Spinhoven et al.
10 citations
Background: Mindfulness-based cognitive therapy (MBCT) is effective in reducing depressive symptoms in patients with major depressive disorder (MDD). Understanding for whom and how MBCT works may allow for improvements in treatment allocation and effectiveness. In this study, our aim was to investigate depressive rumination, content-independent perseverative thinking, mindfulness skills, and...
Journal of Affective Disorders
May 1, 2023
Mira B. Cladder-Micus, J. Vrijsen, A. Fest et al.
BACKGROUND Mindfulness-based cognitive therapy (MBCT) is an evidence-based treatment for depression. The current study focused on the long-term effects of MBCT for chronically, treatment-resistant depressed patients during a 6-months follow-up period. Additionally, predictors of treatment outcomes were explored. METHOD The outcomes of MBCT on depressive symptoms, remission rates, quality of...
PLoS One
2023
Marloes J. Huijbers, Carolien Wentink, Peter L B J Lucassen et al.
Discontinuing antidepressant medication (ADM) can be challenging for patients and clinicians. In the current study we investigated if Mindfulness-Based Cognitive Therapy (MBCT) added to supported protocolized discontinuation (SPD) is more effective than SPD alone to help patients discontinue ADM. This study describes a prospective, cluster-randomized controlled trial (completed). From 151...
Lancet Psychiatry
November 1, 2022
Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jan Spijker et al.
163 citations
Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its efficacy, safety, and tolerability in depression. We searched Pubmed, Embase, and the Cochrane Library and identified three randomised...
Depression and Anxiety
November 9, 2021
J. D. de Klerk-Sluis, Marloes J. Huijbers, S. Löcke et al.
Mindfulness‐based cognitive therapy (MBCT) is effective for relapse prevention in major depressive disorder (MDD). It reduces cognitive reactivity (CR) and rumination, and enhances self‐compassion and mindfulness. Although rumination and mindfulness after MBCT are associated with relapse, the association of CR, rumination, self‐compassion, and mindfulness with relapse before initiation of MBCT...
Journal of Clinical Psychiatry
July 13, 2021
Jolien K E Veraart, Sanne Y Smith-Apeldoorn, Jan Spijker et al.
31 citations
Objective: Ketamine shows rapid and robust antidepressant effects in clinical studies. Psychotic features are an exclusion criterion in most ketamine treatment studies based on the assumption that psychosis will increase with ketamine administration. As patients with treatment-resistant depression (TRD) often have psychotic features, and treatment-resistant depressive symptoms are also common...
BMJ Open
November 12, 2020
Marloes J Huijbers, Carolien Wentink, Anne Speckens et al.
Objectives This study aimed to explore predictors and outcomes associated with different trajectories of discontinuing antidepressant medication (ADM), in recurrently depressed individuals after participation in mindfulness-based cognitive therapy (MBCT). Facilitators and barriers of discontinuation were explored qualitatively.Design Mixed-methods study combining quantitative and qualitative...
Depression and Anxiety
August 8, 2018
Mira B. Cladder-Micus, Anne E. M. Speckens, J. Vrijsen et al.
Chronic and treatment‐resistant depressions pose serious problems in mental health care. Mindfulness‐based cognitive therapy (MBCT) is an effective treatment for remitted and currently depressed patients. It is, however, unknown whether MBCT is effective for chronic, treatment‐resistant depressed patients.
BMC Psychiatry
November 9, 2015
Mira B. Cladder-Micus, J. Vrijsen, E. Becker et al.
BackgroundMajor depression is a common psychiatric disorder, frequently taking a chronic course. Despite provision of evidence-based treatments, including antidepressant medication and psychological treatments like cognitive behavioral therapy or interpersonal therapy, a substantial amount of patients do not recover. Mindfulness-Based Cognitive Therapy (MBCT) has been found to be effective in...